CMPS News and Press, COMPASS Pathways Plc From 02/19/24

2024-02-19 07:00:00 ET Per the consensus of Wall Street analysts, Compass Pathways (NASDAQ: CMPS) stock is on track for an absolutely stellar 12 months. They see its shares rising by 307% compared to where it is today. For reference, a typical year sees the stock market rise by arou...

About 43.8 million adults in the U.S. experience a mental health issue in a given year, according to the National Institute of Mental Health (NAMI). Nearly 16 million of those adults live with major depression. Another 18.1% live with anxiety disorders. And, according to Time.com, “From 20...

Psychedelics such as LSD and hallucinogenic mushrooms may improve sexual function after one undergoes a psychedelic experience. Researchers are reporting the results of a new study, which they believe is the first study to look into the effects of psychedelic substances on sex. For their rese...

At the moment, about 14 million people live with PTSD just in the U.S. Unfortunately, despite extensive clinical research, PTSD is still a significant unmet medical need. However, that may soon change with the US FDA’s acceptance of a New Drug Application from Lykos Therapeutics for MDMA (...

2024-02-12 12:13:32 ET More on ATAI, COMPASS Pathways, etc. Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play Mind Medicine: Positive MM-120 Data Leads To Other 2024 Catalysts De-Risking Psychedelics: Compass Pathways, Cybin And Atai ...

2024-02-09 10:23:18 ET More on COMPASS Pathways ADS Compass Pathways: Psilocybin Developer A Potentially Intriguing, Contrarian Play De-Risking Psychedelics: Compass Pathways, Cybin And Atai Compass Pathways and Greenbrook TMS enter into three-year research collabora...

2024-02-08 17:15:08 ET Summary Compass Pathways plc, a biotech company based in London, is developing a psilocybin-based therapy for CNS disorders. The company's shares declined by over 80% in 2022 due to safety concerns and regulatory hurdles. Psilocybin is classified as a Sc...

2024-02-08 08:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Several Canadian biotechnology companies are poised to make a killing in the Australian market after the county’s Therapeutic Goods Administration (TGA) allowed psychiatrists to prescribe MDMA and psilocybin in 2023. The TGA regulates therapeutic goods such as medical devices and prescri...

LONDON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will hold a fireside chat at the Oppenheimer 34th Annual Healthcare Life S...